Jill Lacy MD

Associate Professor of Medicine (Medical Oncology)

Departments & Organizations

Yale Medical Group

Cancer Center, Yale: Brain Tumor Center | Gastrointestinal Cancer Program | Developmental Therapeutics | Sarcoma Oncology Program

Medical Oncology

Developmental Therapeutics

Research Interests

Clinical research in gastrointestinal malignancies, including gastroesphageal, pancreatic, and colorectal cancers, and brain tumors; Epstein-Barr virus-associated malignancies more...

Education

• M.D., Yale University, 1978

Selected Publications

• Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M,?Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR. Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. Cancer J 13:257-62, 2007
• Srimatkandada P, Loomis R, Carbone R, Srimatkandada S, Lacy J. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases. Eur J Haematol. 2008 May;80(5):407-18. Epub 2008 Jan 23.
• Mayer, T, Lacy, J, Baehring, J. A single institution’s experience with bevacizumab in combination with cytotoxic chemotherapy in progressive malignant glioma. Clinical Medicine: Oncology 2: 455-459, 2008

more...